Cargando…

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell‐depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high‐affinity polymorphisms predict clinical outcomes to alemtuzumab the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keller, Christian W., Ruck, Tobias, McHugh, Donal, Pfeuffer, Steffen, Gross, Catharina C., Korsukewitz, Catharina, Melzer, Nico, Klotz, Luisa, Meuth, Sven G., Münz, Christian, Nimmerjahn, Falk, Wiendl, Heinz, Lünemann, Jan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917309/ https://www.ncbi.nlm.nih.gov/pubmed/31682087 http://dx.doi.org/10.1002/acn3.50935

Ejemplares similares

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis
por: Bruchmann, Maximilian, et al.
Publicado: (2016)

Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis
por: Thomas, Christian, et al.
Publicado: (2018)

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
por: Keller, Christian W., et al.
Publicado: (2021)

Deregulated Fcγ receptor expression in patients with CIDP
por: Quast, Isaak, et al.
Publicado: (2015)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

MS-Versorgung heute und Vision für die Zukunft - eine Rolle für die ASV?
por: Korsukewitz, Catharina, et al.
Publicado: (2022)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
por: Korsukewitz, Catharina, et al.
Publicado: (2020)

Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
por: Korsukewitz, Catharina, et al.
Publicado: (2020)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

IgG-Independent Co-aggregation of FcεRI and FcγRIIB Results in LYN- and SHIP1-Dependent Tyrosine Phosphorylation of FcγRIIB in Murine Bone Marrow-Derived Mast Cells
por: Gast, Mathias, et al.
Publicado: (2018)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Neonatal Fc Receptor–Targeted Therapies in Neurology
por: Nelke, Christopher, et al.
Publicado: (2022)

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function
por: Kleffner, Ilka, et al.
Publicado: (2017)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
por: Schröder, Jens B., et al.
Publicado: (2018)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system
por: Melzer, Nico, et al.
Publicado: (2012)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice
por: Zaytseva, Olga O., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m7pdrledcjsdn0qnhbm031eqgp